SANES

10.632

-0.28%↓

BBVA

19.45

+0.08%↑

BNP

93.27

-0.42%↓

CABK

11.475

-0.39%↓

INGA

25.755

-0.96%↓

SANES

10.632

-0.28%↓

BBVA

19.45

+0.08%↑

BNP

93.27

-0.42%↓

CABK

11.475

-0.39%↓

INGA

25.755

-0.96%↓

SANES

10.632

-0.28%↓

BBVA

19.45

+0.08%↑

BNP

93.27

-0.42%↓

CABK

11.475

-0.39%↓

INGA

25.755

-0.96%↓

SANES

10.632

-0.28%↓

BBVA

19.45

+0.08%↑

BNP

93.27

-0.42%↓

CABK

11.475

-0.39%↓

INGA

25.755

-0.96%↓

SANES

10.632

-0.28%↓

BBVA

19.45

+0.08%↑

BNP

93.27

-0.42%↓

CABK

11.475

-0.39%↓

INGA

25.755

-0.96%↓

Home・Akcijų sąrašas・Ipsen SA.

Ipsen SA.

Atidarymo kaina

SektoriusFinansų sektorius

157.1 -0.06

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

155.2

Max

157.2

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-225M 110M
Pardavimai	36M 1.9B
P/E Sektoriaus vid.	28.534 41.721
Dividendų pajamingumas	0.89
Pelno marža	5.899
Darbuotojai	5,535
EBITDA	-171M 466M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-1.35% downside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.89% 4.65%
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.1B 13B
Ankstesnė atidarymo kaina	157.16
Ankstesnė uždarymo kaina	157.1

Naujienos nuotaikos

By Acuity

38%

62%

107 / 439 reitingas Finance

Ipsen SA. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-05 19:20; UTC

Pagrindinės rinkos jėgos

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026-06-07 23:46; UTC

Rinkos pokalbiai

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

2026-06-07 23:36; UTC

Rinkos pokalbiai

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

2026-06-07 18:00; UTC

Uždarbis

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

2026-06-06 12:40; UTC

Įsigijimai, susijungimai, perėmimai

Correction to Texas Billionaires Article America's Resort -- WSJ

2026-06-06 08:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-06 08:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-06 04:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-06 00:14; UTC

Įsigijimai, susijungimai, perėmimai

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

2026-06-05 21:27; UTC

Uždarbis

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026-06-05 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026-06-05 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026-06-05 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Hog Futures Tumble to Close Week -- Market Talk

2026-06-05 19:10; UTC

Rinkos pokalbiai

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026-06-05 19:03; UTC

Rinkos pokalbiai

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026-06-05 18:59; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026-06-05 18:47; UTC

Rinkos pokalbiai

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026-06-05 18:34; UTC

Rinkos pokalbiai

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026-06-05 18:33; UTC

Įsigijimai, susijungimai, perėmimai

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026-06-05 17:50; UTC

Uždarbis

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026-06-05 17:27; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026-06-05 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026-06-05 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-05 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ipsen SA. Prognozė

Kainos tikslas

By TipRanks

-1.35% į apačią

12 mėnesių prognozė

Vidutinis 155.67 EUR -1.35%

Aukščiausias 215 EUR

Žemiausias 117 EUR

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ipsen SA. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Ipsen SA. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

107 / 439 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.